Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Shanghai Meizer Pharmaceuticals identifies new PROTACs for cancer

May 23, 2022

Chinese researchers disclose BCL2 mutant inhibitors

May 23, 2022

Sichuan Kelun-Biotech Biopharmaceutical patents Raf/Ras kinase inhibitors

May 23, 2022

RORgammat agonist improves efficacy of anti-PD-1 in a murine lung cancer model

May 23, 2022

Biomea nominates third-generation FLT3 inhibitor as IND candidate

May 20, 2022

Spectrum Pharmaceuticals divulges G12C mutant GTPase KRAS inhibitors

May 20, 2022

New phospholipid anticancer target identified

May 20, 2022

Tasquinimod designated U.S. orphan drug for myelofibrosis

May 19, 2022

New YAP1-TEAD interaction inhibitors identified at Vivace Therapeutics

May 19, 2022

TME Therapeutics discovers PIKfyve inhibitors

May 19, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...